HC Wainwright Issues Pessimistic Estimate for KYTX Earnings

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Analysts at HC Wainwright reduced their Q1 2025 earnings estimates for shares of Kyverna Therapeutics in a research note issued to investors on Thursday, April 3rd. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($0.87) for the quarter, down from their previous estimate of ($0.72). HC Wainwright has a “Neutral” rating and a $4.00 price target on the stock. The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.29) per share. HC Wainwright also issued estimates for Kyverna Therapeutics’ Q2 2025 earnings at ($0.89) EPS, Q3 2025 earnings at ($0.91) EPS, Q4 2025 earnings at ($0.94) EPS and FY2025 earnings at ($3.61) EPS.

Separately, Morgan Stanley cut their price objective on shares of Kyverna Therapeutics from $40.00 to $20.00 and set an “overweight” rating for the company in a research report on Tuesday, April 1st. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Kyverna Therapeutics presently has an average rating of “Buy” and a consensus price target of $18.33.

Kyverna Therapeutics Stock Down 3.5 %

KYTX stock opened at $1.91 on Monday. The stock has a 50-day simple moving average of $2.67 and a two-hundred day simple moving average of $3.91. Kyverna Therapeutics has a twelve month low of $1.79 and a twelve month high of $24.91. The firm has a market capitalization of $82.54 million, a PE ratio of -0.55 and a beta of 2.57.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.01).

Hedge Funds Weigh In On Kyverna Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC purchased a new stake in shares of Kyverna Therapeutics during the 3rd quarter valued at $33,000. China Universal Asset Management Co. Ltd. bought a new position in Kyverna Therapeutics in the fourth quarter valued at $34,000. Squarepoint Ops LLC purchased a new stake in Kyverna Therapeutics during the fourth quarter valued at about $43,000. Corton Capital Inc. bought a new stake in Kyverna Therapeutics during the fourth quarter worth about $45,000. Finally, Corebridge Financial Inc. boosted its holdings in shares of Kyverna Therapeutics by 42.3% in the 4th quarter. Corebridge Financial Inc. now owns 12,811 shares of the company’s stock worth $48,000 after purchasing an additional 3,810 shares in the last quarter. Hedge funds and other institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.